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Abstract
Introduction: Retinoic acid signaling pathways are disabled in human breast cancer suggesting a controlling role
in normal mammary growth that might be lost in tumorigenesis. We tested a single receptor isotype, RARa1
(retinoic acid receptor isotype alpha, isoform 1), for its role in mouse mammary gland morphogenesis and mouse
mammary tumor virus (MMTV)-wingless-related MMTV integration site 1 (wnt1)-induced oncogenesis.
Methods: The role of RARa1 in mammary morphogenesis was tested in RARa1-knockout (KO) mice and in
mammary tumorigenesis in bi-genic (RARa1/KO crossed with MMTV-wnt1) mice. We used whole mounts analysis,
stem cells/progenitor quantification, mammary gland repopulation, quantitative polymerase chain reaction (Q-PCR),
test of tumor-free survival, tumor fragments and cell transplantation.
Results: In two genetic backgrounds (129/Bl-6 and FVB) the neo-natal RARa1/KO-mammary epithelial tree was
two-fold larger and the pubertal tree had two-fold more branch points and five-fold more mature end buds, a
phenotype that was predominantly epithelial cell autonomous. The stem/progenitor compartment of the RARa1/
KO mammary, defined as CD24
low/ALDH
high activity was increased by a median 1.7-fold, but the mammary stem cell
(MaSC)-containing compartment, (CD24
low/CD29
high), was larger (approximately 1.5-fold) in the wild type (wt)-
glands, and the mammary repopulating ability of the wt-gland epithelium was approximately two-fold greater.
In MMTV-wnt1 transgenic glands the progenitor (CD24
low/ALDH
high activity) content was 2.6-fold greater than in the
wt and was further increased in the RARa1/KO-wnt1 glands. The tumor-free survival of RARa1/KO-wnt1 mice was
significantly (P = 0.0002, Kaplan Meier) longer, the in vivo growth of RARa1/KO-wnt1 transplanted tumor fragments
was significantly (P = 0.01) slower and RARa1/KO-wnt1 tumors cell suspension produced tumors after much longer
latency.
Conclusions: In vitamin A-replete mice, RARa1 is required to maintain normal mammary morphogenesis, but
paradoxically, also efficient tumorigenesis. While its loss increases the density of the mammary epithelial tree and
the content of luminal mammary progenitors, it appears to reduce the size of the MaSC-containing compartment,
the mammary repopulating activity, and to delay significantly the MMTV-wnt1-mammary tumorigenesis. Whether
the delay in tumorigenesis is solely due to a reduction in wnt1 target cells or due to additional mechanisms
remains to be determined. These results reveal the intricate nature of the retinoid signaling pathways in mammary
development and carcinogenesis and suggest that a better understanding will be needed before retinoids can join
the armament of effective anti-breast cancer therapies.
Introduction
Retinoic acid receptors (RARs) are the main mediators
of the biologic effects of vitamin A, with a long estab-
lished essential role in the maintenance of the differen-
tiated state of epithelial tissues [1]. More recently,
retinoic acid (RA) and other RAR agonists were found
to be growth inhibitory for cancer cell lines in vitro
[2-7], in carcinogen-induced rodent mammary cancer
models, [8-10] and in xenograft models of human can-
cer cell [11-13].
Because pharmacological doses of retinoids were used
in the carcinogenesis studies, the question of the ability
of physiological retinoid levels of vitamin A-replete ani-
mals to exert growth suppressive effects and protect
epithelia from neoplastic transformation remained
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RAR-signaling pathway is defective in carcinomas of
several organs, including breast, mostly due to reduced
expression of RARb or CRBP-1 [14,15]. Whether these
alterations affect oncogenesis or tumor maintenance,
and what might be the mechanism of these effects
remains unresolved.
To address the potential role of RAR both in mam-
mary gland morphogenesis and in modifying cancer sus-
ceptibility at physiological levels of vitamin-A, we used
RARa1 homozygous null (RARa1/KO) mice and bi-
genic mice generated by crossing RARa1/KO with
MMTV-wnt1 transgenic mice. We found that loss of
RARa1 produced, in pubertal glands, a highly branched
ductal epithelial tree phenotype, which was epithelial
cell autonomous. Because retinoids are well known for
regulation of embryonic stem cells [12,16-18], and, in
one case, adult HSCs [19], and because adult stem cells
are known to be involved in mammary gland morpho-
genesis [20-27], we hypothesized that loss of RARa
might affect the mammary stem cell compartment.
Moreover, because wnt1 oncogenesis is believed to tar-
get mammary stem cells or bi-potent progenitors and
might be responsible for progenitor amplification
[20,28-30], we predicted that the RARa1/KO glands
with the complex epithelial tree phenotype, will be more
susceptible to wnt1-tumorigenesis.
We now show that epithelial cells derived from the
highly branched ductal mammary tree of the RARa1/KO
glands contain higher percentage of luminal progenitor
cells, that they form larger primary mammospheres when
cultured under adhesion-free and serum-free conditions,
and that their MaSC-containing compartment is smaller
than that of the wild type (wt)-glands. We further show
that activation of RARa by a specific agonist inhibits pri-
mary wt-mammospheres growth. Our published work
[31], showed that chronic treatment of MMTV-wnt1 mice
with the same RARa agonist inhibited mammary tumor
formation and growth. In spite of all these inhibitory
effects of activated RARa we found a significant increase
in tumor-free survival when mice null for RARa1 were
crossed with MMTV-wnt1 transgenic mice. We propose
that in vitamin-A replete conditions, RARa guards normal
morphogenesis and influences wnt-induced tumorigenesis
at least in part by maintaining a proper hierarchy of the
mammary epithelial compartments.
Materials and methods
Animals
RARa1-/- mice (129/Bl-6 background) were generated
in Pierre Chambon’s laboratory (IGBMC, Strasbourg,
France), and MMTV-wnt1 mice (FVB, SJL, and Bl/6
mixed background, with FVB prevalence) were gener-
ously provided by Dr. Yi Li (Baylor College of Medicine,
Houston, TX, USA). The RARa1-/+ female mice were
crossed with hemizygous male MMTV-wnt1 mice
followed by intercrossing of F1 progeny that was
RARa1+/- and MMTV-wnt1 transgenic, until sufficient
mice for study were obtained. Genotyping was carried
out by PCR. To obtain RARa1- / - in FVB background
RARa1+/- females were backcrossed eight times with
FVB males. All animal experiments were conducted in
accordance with the IACUC approved protocols follow-
ing the Mount Sinai Guidelines.
Whole mounts of mammary glands and quantification of
side branching and mature terminal end buds
Mammary glands were excised, fixed in Carnoy’s fixative
and stained in carmine alum solution as described in
reference 32 [32]. The neonatal glands were photo-
graphed and JPG files analyzed using the ImageJ soft-
ware. The entire mammary tree in the abdominal
number four gland/group was circumscribed and the
Integrated Density of the area was measured in pixels.
T h eb r a n c hp o i n t sw e r ec o u n t e di nt h et h r e el a r g e s t
ducts in seven pairs (a total of 14 glands) of number
four glands from the nipple to the periphery of the fat
pad and the mature terminal end buds along the periph-
ery of the fat pad.
Mammary gland transplantation
Fragments (approximately 2 mm
3, approximately 30,000
cells) of mammary glands of 8- to 10-week-old virgin
mice (wt or RARa1/KO) taken from the area between
the nipple and the LN, were transplanted into epithe-
lium pre-cleared glands of three-week-old wild type or
RARa1/KO animals, as previously described [33]. The
recipient glands were excised and processed as for
whole mounts eight weeks after transplantation. Seven
mice were sham transplanted.
Quantification of stem/progenitors using FACS analysis
Mammary gland numbers four and five of seven- to eight-
week-old female mice were isolated, minced and digested
in trypsin/collagenase. The epithelium was freed of adipo-
cytes by centrifugation and red blood cells were lysed.
The remaining cells were treated exactly as described [34].
For the characterization of MaSC-containing and luminal
progenitor containing compartments, cells (1 × 10
6 cells/
sample in duplicate) were incubated with PE or APC-
conjugated anti-CD24 Ab (BD Pharmingen, San Jose,
CA, USA), APC-conjugated anti-CD29 Ab (Invitrogen,
Camarillo, CA, USA) and FITC-conjugated anti-CD61 Ab
(eBioscience, San Diego, CA, USA). In all other flow cyto-
metry experiments, ALDH activity was determined by the
Aldefluor assay according to manufacturer’s directions
(Aldegen, Durham, NC, USA), followed by CD24 antibody
(1:100, biotin conjugated, BD Pharmingen, secondary
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ice for 30 minutes). A pool of cells from approximately
10 mice was routinely used for each experiment. FACS
analysis was carried out using a FACScanto flow cyt-
ometer, DIVA software program for acquisition (BD Bios-
ciences) and Flowjo (Treestar, Inc. Ashland, OR, USA)
software for analysis.
Growth of mammospheres
Mammary epithelial cells prepared as described for
FACS analysis were further dissociated by pipetting and
filtering through a 40 μ pore cell strainer. (Occasional
small clumps of up to six cells remained). Between 2.5
to 5.0 × 10
4 cells were plated in ultra low adhesion
24-well plates (Corning, Corning, NY, USA) and incu-
bated in serum-free F12/DMEM 50:50 medium (Cellgro,
Mediatech, Inc., Manassas, VA, USA) supplemented
with 20 ng/ml EGF and 1:50 B27 Supplement (Invitro-
g e n ,C a r l s b a d ,C A ,U S A ) .W h e nt r e a t m e n tw a si n d i -
cated, the agonist and antagonists were added after 8 to
10 days of incubation at 10 nM for Am580, 200 nM for
at RA, and 10-fold excess of Ro41-5253 RARa antago-
nist, 100 nM or 2 μM, respectively, and the mammo-
spheres were incubated for approximately eight days
with partial medium and drug replenishment every two
days. Mammospheres from four to eight wells were
combined, allowed to settle at 1 g, dissociated with
EDTA, Joklik’s medium and a brief trypsin treatment,
followed by Soybean trypsin inhibitor (Sigma, St. Louis,
MO, USA) and cells from at least duplicate culture
pools were counted either in hemacytometer or in 5 μl
droplets in duplicates. For second passage the disso-
ciated cells were re-plated as above. In some experi-
ments mammospheres were counted before dissociation.
Expression of RAR by Q-PCR
RNA was isolated from primary mammary epithelial cells
using RNeasy kits (Qiagen, Valencia, CA, USA), according
to the manufacturer’s protocol. cDNA was synthesized
from 2 μg of RNA using RevertAid M-MuLV reverse tran-
scriptase (Fermetas, Geln Burnie, MA, USA). Q-PCR was
performed using the 2 × SYBR Green master mix (Applied
Biosystems, Carlsbad, CA, USA) with 300 nM primers and
40 ng of cDNA. To determine the fold change in expres-
sion, the Ct value was averaged from triplicates for each
sample. To normalize the RARs expression, triplicates for
Ct from the RAR gene was averaged and divided by the
average of the triplicate from the GAPDH gene. The PCR
primers used were: RARb2 for: 3’ CTT CCT CCT GCA
TGC TGC AG 5’, RARb2 rev: 5’ GG CAC TGA CGC
CAT AGT GGT A 3’; RARg1 for: 3;’ TGG GGC CTG
G A TC T GG C TA5 ’, RARg1 rev: 5’ AT CTC CTC CGA
GCT GGT GCT 3’; RARg2 for: 3’ CGG ACT TGA GTC
TTT TGC CTG 5’, RARg2 rev: 5’ GCT CTG TGT CTC
CAC CGA TT 3’.
Activation of wnt-pathway
Cells from three individual MMTV-wnt1 tumors in the
first or second passage in culture, were transfected with
the b-catenin reporter TOP-FLASH plasmid and renilla
luciferase plasmid (pRL-SV4) in triplicates using Lipo-
fectamine LTX (Invitrogen). After approximately 20 hr
incubation, 4 μM Ro41-5253 was added and 24 hr later
the cells were lysed in 1 × passive lysis buffer (Dual-
Luciferase Reporter Assay System, Promega, Madison,
WI, USA) and assayed for luciferase using the Dual-
Luciferase reporter (DLR) Assay System (Promega).
Identification of bi-potential cells in mammospheres
Eight-day-old mammospheres were dissociated and plated
at one cell/20 μl of medium in 96-well plates (400 wells).
Wells with single cells (118 total) were marked and incu-
bated in medium with serum with weekly medium
changes for a month. Of these only 21 produced colonies;
these were stained with anti-CK14 (Neomarkers, Fremont,
CA, USA; 1:200, secondary anti-rabbit-Alexa 488, 1:500,
Molecular Probes, Invitrogen) and anti-CK18 (Sigma, St.
L o u i s ,M O ,U S A ;1 : 4 0 0 ,a n t i - m o u s e - A l e x a5 6 8 ,1 : 5 0 0 ,
Molecular Probes) and DAPI, examined under fluorescent
Nikon Eclipse E600 microscope and photographed
with SPOT-RTTM camera, Spot Diagnostic Instruments
(Sterling Height, MI, USA) (× 200).
Kaplan-Meier disease-free survival curves
MMTV-wnt1 and MMTV-wnt1-RARa1/KO mice were
palpated weekly (all five-gland pairs were examined) by
the same investigator. The appearance of the first palp-
able tumor was recorded. Mice were euthanized when
tumors reached a size of approximately 1 cm
3 and parts
of the tumors were taken for histological analysis (for-
malin fixation), RNA analysis (RNAlater), and in some
cases for preparation of primary cultures and/or trans-
plantation. Histological analysis of the tumors was per-
formed by the Mutant Mouse Pathology Laboratory at
UC Davis and by Mount Sinai’s Center for Comparative
Medicine and Surgery. Statistical analysis was done
using the Log-rank test for the Kaplan-Meier survival
studies and by two-way ANOVA test for the tumor
growth studies. Significant differences were considered
at P < 0.05. Specific methods are indicated in figure
legends.
Tumor transplantation
For transplantation, fragments (approximately 1 mm
3)o f
MMTV-wnt1 and MMTV-wnt1-RARa1/KO tumors
were transplanted with an implant needle (Fisher,
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numbers three and four of anesthetized eight-week old
FVB mice (four mice per experiment, repeated three
times). Each transplant consisted of three randomly cho-
sen tumor fragments from a mince. Tumor diameter
was measured twice a week with a caliper. For determi-
nation of tumor latency and tumor take, primary wnt or
RARa1/KO-wnt tumors were dissociated, the single cells
counted and 10
5 or 10
4 viable cells were injected into
FVB mice as above.
Results
We studied a single RAR isoform knockout (KO) mice
(RARa1/KO) because compound RAR mutants are
embryonic or perinatal lethal whereas, with some excep-
tions, single isoform mutants are viable, fertile, and have
a normal life span. We focused in this work on the role
of the RARa1 isoform which, directly, or through RARb
expression, has been implicated in growth suppression
of normal and cancerous breast cells in vitro [2,6,7].
RARa controls mammary development before and during
puberty
We analyzed RARa1/KO, and wild type (wt) mammary
whole mounts from female mice of 129/C57Bl-6
genetic backgrounds in the first week after birth, dur-
ing puberty, pregnancy, lactation, involution and post-
involution and mice in FVB background after birth
and during puberty. (Two genetic backgrounds were
used because mammary morphology has been shown
to be genotype-dependent [35,36]). A major effect of
RARa1/ K Ow a sf o u n di nt h en e w b o r na n dt h ep u b e r -
tal glands (Figure 1A-E); other developmental phases
were ostensibly normal, (Results not shown). In the
RARa1/KO neonatal glands of 129/C57Bl-6 and FVB
mice the epithelial ductal tree extended approximately
two-fold further into the fat pad (Figure 1A). In puber-
tal wt-glands, (six to eight weeks old) at diestrus the
ductal tree filled most of the fat pad but several term-
inal end-buds (sites of active proliferation) still
remained (Figure 1B, E, left panels). (The phenotype
was also present in other parts of the estrus cycle,
results not shown). There was a two-fold increase in
branch points and a five-fold increase in the number
of mature end-buds in the RARa1/KO fad pad (Figure
1C, D). This effect was specific to RARa1/KO as
RARb2/KO mice did not show a change in branching
morphogenesis (results not shown) and RARa1/KO
produced similar branching phenotype in two different
genetic backgrounds (Figure 1B, E, whole mount and
histological sections). Thus, loss of a single RAR iso-
form has a major effect on the expansion of the neona-
tal ductal tree and branching morphogenesis in
pubertal mice.
The increased ductal branching is predominantly
epithelial-cell autonomous
To exclude systemic effects of RARa1/KO on mammary
morphogenesis, epithelium-containing mammary frag-
ments, estimated to contain approximately 30,000
epithelial cells, were transplanted from adult FVB-wt or
RARa1/KO donor mice into epithelium-divested,
abdominal number four glands of FVB-wt and RARa1/
KO, three-week old recipient mice such that the experi-
ment was always internally controlled. The transplanted
number four glands and the number three glands from
the recipient mice, used as internal controls, were
excised eight weeks later, and their phenotype examined
in whole mounts. We found (Figure 2) that donor tissue
from wt and RARa1/KO mice was able to repopulate
the recipient glands; the highly branched ductal tree
of the RARa1/KO donor was fully reconstituted in a wt-
FVB recipient, indicating that the phenotype was epithe-
lial cell autonomous. The “penetrance” of the KO-
phenotype was slightly greater when both the donor
and the recipient mouse were of the KO-type, (75% KO-
phenotype in wt-recipients and 86% in RARa1/KO reci-
pients, Table 1), suggesting possibly a minor systemic
effect. The majority (86% and 87%) of wt-FVB trans-
plants had the expected wt-phenotype in the FVB-wt
and RARa1/KO recipients, (Table 1).
Primary RARa1/KO mammary gland mammospheres
contain more cells
We wondered whether the increased branching and,
presumably, the increased epithelial content of the
RARa1/KO gland is a result of a larger stem/progeni-
tor cell pool. As a first test of this idea we prepared
single cell suspensions of partially purified mammary
epithelial cells from glands of seven- to eight-week-old
wt or RARa1/KO mice, seeded them under mammo-
spheres conditions, dissociated the mammospheres
after eight days of attachment-free growth and counted
the individual cells [37]. As shown in Figure 3A, in
four independent experiments, wells seeded with
RARa1/KO derived epithelium produced mammo-
spheres that, upon dissociation, had approximately
two-fold more cells (P = 0.01) than those obtained
from wt-epithelium. The difference in the number of
mammospheres, which were difficult to count, was
slightly and not significantly lower in the RARa1/KO
cultures. We were unable to efficiently passage any
mammospheres beyond Passage 3.
Although, mammospheres are considered to be useful
culture correlates to stem cells, it appears that only a
small percent of mammosphere cells have repopulating
in vivo potential, and their derivation and composition,
especially in the mouse mammary, is still debated
[25,38]. We characterized the primary mammospheres
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was done by inoculating single cells obtained from pri-
mary mammospheres into small wells, and when colo-
nies were established, staining them for cytokeratin
CK14 (myoepithelial cells) and CK18 (luminal cells). Of
a total of 118 wells with single cells which started divid-
ing, only 21 (18.6%) formed, after a month of incuba-
tion, large enough colonies to be stained with antibodies
t oC K 1 4a n dC K 1 8 .W ef o u n d( F i g u r e3 B )t h a to n l y
3 0 %o ft h ec o l o n i e sp r o d u c e db ys i n g l ec e l l sw e r eb i -
potential, with individual cells within the colony expres-
sing either CK18 or CK14; 55% of the colonies
expressed exclusively CK18, (luminal), and 15% exclu-
sively CK14 (myoepithelial) markers. Thus more than
80% of cells in mammospheres are unable to produce
colonies in adherent culture, and of those cells that
make colonies, only approximately 30% are bi-potential.
RAR-activation is involved in growth of primary
mammospheres
To better link the increase in cell number in the
RARa1/KO-derived mammospheres with the RAR path-
way, wt-mammary epithelial cells were allowed to form
mammospheres and were either left untreated or were
Figure 1 The effect of RARa1/KO on neonatal and pubertal gland development. (a) Effect on the size of the neonatal glands. Number 4
glands were dissected from five to six days old wt and RARa1/KO C57Bl/6 or FVB, four mice per group, and whole mounts were prepared as
described in Materials and methods. The area taken up by the mammary tree was analyzed using the Image J software. Bars are mean and SD
of four glands per group. (b-e) Effect on pubertal mammary tree branching morphogenesis and terminal end buds. Number 4 mammary glands
from seven to eight weeks old wt or RARa1/KO C57Bl/6 (b-d) and FVB pubertal mice (e) were dissected and processed for whole mounts and
paraffin sections. Branching points were counted along the entire length of the three longest ducts. Bars show mean and SD of seven pairs (14
total) of number 4 glands per group (P = 0.0001, t-test). The same glands were used to count the peripheral terminal end buds (TEBs) (P =
0.00001, t-test).
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nist) or with Am580 combined with a 10-fold excess of
Ro41-5253, a RARaantagonist, at which time the mam-
mospheres were enzymatically dissociated and single
cells counted. We found that activation of RARa by
Am580 reduced mammosphere growth by 50%, while
RARa-antagonist in presence of Am580, completely
reversed this inhibition (Figure 3C), mimicking to some
degree the loss of RARa1.W ea l s of o u n dt h a t
mammospheres treated with 100 nM atRA, an agonist
for all three RARs, in presence of the specific RARa
antagonist, boosted the cell number in mammospheres
even above that of untreated controls (Figure 3C). Com-
parison of RAR expression by Q-PCR in RNAs extracted
from wt and RARa1/KO epithelial cells isolated directly
from the mammary glands, showed that all three RAR
isotypes were present, but while there was no difference
in RARa1/2 and RARb2 expression (results not shown),
Figure 2 Mammary gland transplantation. Fragments of epithelium containing mammary glands of eight to ten weeks old virgin mice (wt or
RARa1/KO) were transplanted into number 4 glands pre-cleared of epithelium of three weeks old wild type or RARa1/KO animals (see Materials
and methods). At week 11 (eight weeks after transplantation) the transplant-recipient glands and intact glands number 3 from the same mouse,
as control, were processed for whole mounts. >90% of wt-FVB transplants repopulated the recipient gland while <50% of the FVB-RARa1/KO did
(see Table 1).
Table 1 Epithelial-autonomous phenotype of RARa1-null phenotype
Categories RARa1-null to FVB RARa-null to RARa-null FVB to FVB FVB to RARa-null
Total number transplanted 17 18 30 17
Successful gland repopulation (%) 47.0 39.0 93.3 94.1
Expected phenotype (%) 75.0
1 86.0
1 86.0
2 87.0
2
1 Increased ductal tree branching, more total and mature TEBs,
2 Normal branching phenotype.
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increased by almost two-fold in the RARa1/KO cells
(Figure 3D). Our previous work [31], showing a pro-
proliferative role of RARg suggests that, in addition to
blockade of the RARa,t h ei n c r e a s e dR A R g1m i g h th a v e
contributed to the cell increase in mammospheres trea-
ted with atRA and Ro41-5253 (Figure 3C). Whether this
effect was mediated through a specific effect on the pro-
genitors remains to be determined.
RARa1 loss affects mammary epithelial hierarchy and
mammary repopulating efficiency
We first tested the effect of RARa1/KO on the stem/
progenitor compartment of the mammary epithelium.
This was done by determining the percent of cells
expressing low levels of CD24 antigen (CD24
low)a n d
showing high ALDH activity (ALDH
high)i nc e l ls u s -
pensions of partially purified mammary epithelial cells
from glands of seven- to eight-week-old wt or RARa1/
Figure 3 Growth, composition and regulation of primary mammospheres. (a) Comparison of mammosphere growth. Primary cells obtained
from wt and RARa1/KO mammary glands, were inoculated at 2.5 to 5 × 10
4 under conditions of ultra-low adhesion and serum-free medium and
eight days later, the mammospheres were disassociated and the cells counted (see Materials and methods). The bars show mean (4,750 and
8,833 cells respectively, and SD of three individual experiments and three to four samples per group; P = 0.04 by unpaired t-test. (b) Bi-potential
cells in mammospheres. Primary mammary epithelial cells were incubated for eight days until most single cells died; mammospheres were
dissociated, inoculated into 96 wells, at 1cell/well (see Materials and methods) and when colonies formed stained for CK18 and CK14. (Red -
CK18; green - CK14; blue - DAPI). Total number of colonies stained = 21. Scale bar = 10 um. (c) Regulation of mammosphere growth by
retinoids. Cells isolated from mammary glands of seven- to eight-week old FVB mice were inoculated under conditions of mammosphere
formation and eight to ten days later were treated with 10 nM of Am580, 200 nM of atRA, and/or 10-fold excess (100 nm and 2 μM,
respectively) of RARa antagonist, Ro41-5253 for seven to eleven days. Each symbol represents an individual well; there were two to four wells
per experiment, and a total of four experiments. Kruskal-Wallis test P = 0.0002; *indicates significance at P < 0.05 by Dunn’s Multiple Comparison
Test. (d) RARg1 expression. RNA was extracted from freshly isolated and partially purified mammary epithelial cells and wt and RARa1/KO, and
subjected to Q-PCR analysis as described in Materials and methods. The bars show mean of three experiments, two samples in each.
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population encompassing the mammary repopulating
cells but also progenitors [24,34,40]. A representative
FACS analysis (Figure 4A) shows that the RARa1/KO
epithelium contains more CD24
low ALDH
high cells
than wt-epithelium. In a total of seven experiments
(Figure 4B), we found a statistically significant, (P =
0.01), median 1.7-fold increase in these cells in
RARa1/KO glands. To test which specific subpopula-
tions were affected by the loss of RARa1,w eu s e da n
additional surface marker, (CD29). Populations of
CD24
low cells with high expression level of CD29 (and/
or CD49f) represent the MaSC-containing compart-
ment, while CD24
high/CD29
low are considered to be
luminal progenitors [25]. As shown in Figure 4C, the
RARa1/KO mammary epithelium contained greater
percentage of progenitors (CD24
high/CD29
low) but
fewer MaSCs (CD24
low/CD29
high)t h a nw tg l a n d s .
Importantly, the ratio of progenitors/MasSCs in the
RARa1/KO epithelium was 1.9, while in the wt glands
it was only 0.8. Both progenitors and MaSC-compart-
ment were positive for CD61 (results not shown).
Figure 4 Characterization of the stem/progenitor cell compartment of wt-FVB and RARa1/KO. (a) Representative histograms of flow
cytometry analysis of CD24
low/ALDH
high compartment in mammary epithelium. Primary mammary epithelial cells (approximately1 × 10
6) were
incubated with ALDH substrate with inhibitor (first and third from left upper and lower panels) or without inhibitor (second and fourth from left
upper and lower panels) followed by incubation with anti-CD24 Ab and detected with secondary Ab (APC-conjugated) as described in Materials
and methods. Inclusion of the DEAB inhibitor reduced the ALDH activity by 82 and 87%, in FVB and RARa1/KO cells, respectively. Gated:
CD24
low/ALDH
high (b) Summary of seven individual experiments. Experiments were performed as in A, shown are median, 3.9% and 6.7%
respectively, (mean 4.4% and 6.6%, respectively, P = 0.04, unpaired t-test).
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wt glands suggest that these epithelium might be more
effective in repopulating epithelium-divested mammary
glands. To test this we transplanted mammary frag-
ments containing approximately 30,000 cells which,
according to published reports [25] should contain 1 to
10 stem cells). As shown in Table 1, while >90% of the
wt-donors produced successful transplants, only 47% of
RARa1/KO mammary fragments were successful when
transplanted into wt-mice. (The rate went down to 39%
when the recipients were RARa1/KO mice). Thus, simi-
lar size fragments of RARa1/KO glands contain propor-
tionally fewer stem cells, or contain stem cells with
impaired activity. Although, preliminary, this finding is
in agreement with the increased MaSC-compartment of
the wt-mammary (Figure 5) and suggests that loss of
RARa1/KO may alter the normal hierarchy of mammary
epithelium.
Loss of RARa1 delays mammary tumor development in
MMTV-wnt1 mice, slows the growth and increase latency
of transplanted tumors
The target cell of wnt1-oncogenesis in mammary gland
has been identified as the stem cell, the progenitor or
both. It has been also shown that wnt1 can expand and
change the stem cell compartment [20,28,41,42]. We
confirmed, using CD24
low/ALDH
high as markers, that
epithelial cells from MMTV-wnt1-glands had a much
higher proportion of these cells (mean 8.2% Figure 6A)
than wt-glands and their content was further increased
(mean 11.2%, Figure 6A and 6B) in the bi-genic
(RARa1/KO × MMTV-wnt1) mammary glands. We
noted that unlike the wt-cells, which had distinct high
and low CD24 populations, the wnt1 expressing cells
had a more homogenous and lower expression of CD24,
precluding their further sub-division based on this mar-
ker. This change has been seen previously [20,28,41,42].
Since both stem cells and progenitors are considered to
be wnt1-targets, the changes we observed in these com-
partments made it difficult to predict what effect the
loss of RARa1 will have on mammary tumorigenesis. To
test this, mammary glands of 40-MMTV-wnt1 and 42-
MMTV-wnt1-RARa1/KO young female mice were pal-
pated weekly for 40 weeks, and the appearance of palp-
able tumors was recorded. Mice were sacrificed and the
tumors collected when they reached the size of approxi-
mately 1 cm
3. Kaplan-Meier analysis showed that the
overall tumor-free survival was significantly (P = 0.0002)
longer in the bi-genic mice and that, compared to
MMTV-wnt1 mice, approximately three times as many
Figure 5 Characterization of MaSC-containing and luminal progenitor containing compartments. Mammary epithelial cells isolated as in
Figure 4A, were incubated with PE-conjugated anti CD24 Ab, or APC-conjugated anti CD29 Ab and analyzed as described in Methods. Gated:
upper left (FVB) and upper second from left (RARa1/KO) for CD24
high/CD29
low (luminal progenitors, upper left square) and for CD24
low/CD29
high
(MaSC, lower right square). The third and fourth upper squares-negative controls, cells incubated with conjugated IgGs. The results shown are of
one experiment, which was repeated once.
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Page 9 of 14MMTV-wnt1-RARa1/KO mice were tumor-free at the
end of the 40
th week follow up (Figure 6C). H&E stained
sections of the wnt1 and bi-genic tumors had similarly
typical wnt-histology (results not shown). This result
suggests that the reduction in the MaSCs containing
sub-population, by reducing the target population,
might be one mechanism through which RARa1 loss
slows down wnt1-oncogenesis.
Because these experiments were done in mice with
germ line KO of RARa1, to link the effect to the tumor
itself, we transplanted fragments of wnt1-RARa1/KO
and wnt-tumor on the contralateral sides of four wt-
mice between the third and the fourth mammary gland.
The mice were palpated weekly and once tumors were
detected, their diameters were measured every three
days. Figure 6D shows that between Day 8 and 17 the
Figure 6 Wnt1-tumorigenesis and wt and RARa1/KO transplanted tumor growth. (a) Representative histograms of flow cytometry analysis
of CD24
low/ALDH
high cells in FVB-wnt1 and FVB-wnt1-RARa1/KO- mammary glands. Primary mammary cells were isolated from glands of seven-
week-old mice and processed for flow cytometry analysis as described in Figure 3. (b) Summary of flow cytometry experiments. The experiments
were carried out as in A; each dot represents individually processed sample. Statistical analysis, two way ANOVA, P = 0.0025. (c) Tumor-free
survival (Kaplan-Meier curve). Forty female mice transgenic for Wnt1 and wt-RAR and 42 RARa/KO were allowed to age and were examined at
regular intervals for the appearance of a palpable tumor nodule. The difference in disease-free survival (percent of tumor-free mice), plotted as a
function of post-natal age (Kaplan-Meier curve) was statistically significant (P = 0.0002). (d) Transplanted MMTV-RARa1/KO-wnt1 tumor fragments
have slower growth rate than MMTV-wnt1 tumors. Fragments of randomly chosen pairs of MMTV-wnt1/wt and MMTV-wnt1/RARa1/KO tumors
were transplanted into the opposite flanks of wt-FVB hosts. The tumors were measured every three days. The bars show mean and SE (n =1 2
per group, P = 0.01. two-way ANOVA test). (e) Inoculation of MMTV-wnt1/RARa1/KO cell suspensions produces tumors after longer latency. Cell
suspensions (10
5 and 10
4) prepared from a pair of similar size MMTV-wnt1/RARa1/KO and MMTV-wnt1 tumors were inoculated into eight to ten
FVB-mice, (as in D) and appearance of palpable tumors was recorded and plotted as fraction of tumor-free mice vs. days post-inoculation
(Kaplan-Meier).
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Page 10 of 14wt-wnt1-derived tumors showed a small growth advan-
tage over the wnt1-RARa1/KO tumors, but in the next
seven days they grew exponentially, reaching the weight
of 500 mg, (calculated from the measurements of tumor
diameter), while the growth of wnt1-RARa1/KO tumor
leveled off at about 60 mg. Thus, even in a RAR-intact
systemic environment, the growth of transplanted tumor
cells lacking RARa1 was delayed.
To measure tumor latency, 10
5 and 10
4 single cell sus-
pensions obtained from wnt1 and wnt1-RARa1/KO
tumors were injected as above and the time of palpable
tumor appearance was recorded. Figure 6E (Kaplan
Meier plot) shows that, at both cell concentrations, cells
derived from the wnt1-RARa1/KO tumors had much
longer latency.
Discussion
Our results provide evidence that at physiological levels
of vitamin A, a single RAR isoform, RARa1 participates
in the control of normal branching morphogenesis of
the pubertal mammary epithelial tree. This is evidenced
by the excessive side budding and secondary branching
observed in mice of two genetic backgrounds when
RARa1 is knocked out (Figure 1). Although, control of
mammary morphogenesis is complex and can be driven
by both systemic [43-45] and local [46-48] effects, our
mammary transplantation experiments results (Figure 2
and Table 1) indicate that in this capacity, RARa1 func-
tions in a predominantly epithelial-cell autonomous
fashion. In addition to the effects in the pubertal gland,
we found that loss of RARa1 causes doubling of the
rudimentary mammary tree in the neonatal gland (Fig-
ure1), suggesting a possible role for this receptor in
embryonic mammary development. A similar branching
phenotype has been described in transgenic mice over-
expressing a DN-RAR mutant, which blocks all retinoid
signaling [49], but, to the best of our knowledge, ours is
the first described link between a single RAR isoform
and mammary epithelial growth and morphogenesis in
vitamin A replete animals.
Based on the increased epithelial cellularity of the
KO-glands and published data implicating RARa in anti-
cancer activity, we expected that the RARa1/KO mice
crossed with the MMTV-wnt1 mice will be more suscep-
tible to wnt1-induced tumorigenesis. Moreover, activa-
tion of retinoid signaling has been shown to inhibit the
wnt1 pathway in cell culture [50,51]. Indeed, treatment of
cells derived from three individual wnt1-tumors and
transfected with a reporter for wnt1 pathway activation
(TCF/b-catenin activity), when treated with an RARa
antagonist, Ro415253 produced a significant (P = 0.01)
two-fold increase in the reporter (luciferase) activity
(results not shown). However, unexpectedly, we found
that MMTV-wnt1-RARa1/KO mice had significantly
longer tumor-free survival than MMTV-wnt1 wt-mice
(Kaplan Meier analysis, Figure 6). Moreover, in three
independent experiments fragments of wnt1-RARa1/KO
tumors grew much more slowly than fragments of wnt1
tumors when implanted into contra lateral sides of the
same mouse, and single cells suspensions obtained from
wnt1-RARa1/KO tumors showed much longer latency.
H o wi si tp o s s i b l et h a ta c t i v eR A R a1 which prevents
apparent epithelial hyperplasia and blocks wnt pathway
activity, also allows a more efficient wnt1-induced onco-
genesis? The oncogenic targets of wnt1 are believed to
be progenitor/stem cells [28,29] and wnt signaling might
h a v ear o l ei nm a m m a r ys t e mc e l l ss e l f - r e n e w a l[ 2 4 ] .
The uncertainty regarding the precise target comes from
the difficulty in comparing stem cell compartments in
normal mammary and in wnt1 induced tumors. The
situation is further complicated by the findings [42] that
in the pre-neoplastic stage constitutive wnt1 signaling
perturbs the epithelial hierarchy, leading to the emer-
gence of aberrant multipotential stem-like cells in the
committed luminal cell fractions. How can then our
result fit into this complex scheme? We showed that
pre-malignant wnt1-RARa1/KO-glands have the highest
content of ALDH
high/CD24
low cells and that pubertal
RARa1/KO mammary gland (without wnt1-expression)
contains 1.7 times more of these cells than wt-mammary
(Figures 4 and 5). Cells isolated from RARa1/KO and
mammospheres produced by the RARa1/KO cells form
larger mammospheres (Figure 3), possibly because the
progenitors might prolifera t em o r er a p i d l y .T h e s ep r o -
genitors were shown to be elevated during puberty, con-
comitant with an increased ductal branching and
elongation, a phenotype that is enhanced in the RARa1/
KO mice [52]. At the same time, however, we found a
reduction in MaSc-enriched compartment and a reduc-
tion in repopulation efficiency of RARa1/KO mammary-
fragments (Figure 2 and Table 1). Although, we did not
perform consecutive in vivo passages of the transplants,
the diminished capacity of the RARa1/KO fragments to
repopulate, suggests that they contain fewer stem cells
or, at the least, they contain stem cells with diminished
activity.
That RARa1 keeps in check the proliferative capacity
of the progenitors in the pubertal gland and, that its
loss leads to the enlargement of the progenitor compart-
ment, fits with the established anti-proliferative role of
RAR and retinoids. For example, p27
kip,ap r o t e i nt h a t
accumulates in response to RAR activation, can limit
the self-renewal of some adult tissue progenitors [53]. It
is also possible, that in addition to removing a block to
proliferation, loss of RARa1/KO provides an indirect
proliferative stimulus mediated through RARg1. We
showed that RARa1/KO epithelium has higher levels of
RARg1-mRNA (Figure 3D), and that this isoform has
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Page 11 of 14pro-proliferative activity in mammary cells [31]. More-
over, wt-mammospheres treated simultaneously with
atRA and an RARa antagonist, a combination that
allows RARg (and b) activation (Figure 3C), yielded the
highest numbers of cells.
Overall, our current data suggest that the profound
reduction in mammary repopulating activity combined
with the predominance of progenitors over MaSC-
containing compartment in the RARa1/KO, by reducing
wnt1 target might contribute to the delay in wnt1-
tumor development. The mechanism for this is
unknown, but it has been shown that PTEN loss in
HSCs causes a transient expansion of the stem cell pool
followed by its depletion [54,55]. We have shown that
RAR activation inhibits PI3K activity, thus loss of
RARa1 might possibly cause a similar effect to that of
PTEN deletion. In an elegant study Purton et al.[ 1 9 ]
have shown that loss of RARa1,b u tn o tR A R a,r e s u l t s
in reduced numbers of HSCs and increased numbers of
more differentiated progenitor cells in the mutant mice.
Although, in the mammary it is the RARa that appears
to be involved, different RAR isotypes are known to
have tissue-specific roles [17,56].
Because wnt1 pathway activation is involved in human
breast cancer [57], and RARa has a proven role in
breast cancer, the mechanism connecting RARa1t o
control of wnt-tumorigenicity is worthy of further study.
It remains to be determined whether a reduction in
stem cell level in RARa1/KO mice translates into
reduced cancer stem cell level, what is the mechanism
responsible for this reduction and whether it is the
cause of increased tumor-free survival and a delay in
growth of transplantable tumors.
I ns u m m a r y ,w es h o w e dt h a tl o s so fRARa1 leads to
reduced mammary stem cell content and an increase in
wnt1-tumor free survival in mice. Under physiological
conditions RARa1 signaling appears to control the con-
tent of mammary stem/progenitor cell compartments
and affect the proper morphogenesis of neonatal and
pubertal mammary gland.
Conclusions
The established anti-proliferative effect of retinoids on
breast cancer in culture and in selective in vivo models
did not translate, so far, into a successful anti-breast can-
cer therapy. Our results led us to conclude that retinoic
acid receptor isotypes might have unique functions in
normal development and in oncogenesis and that some
of the functions can only be discerned in vivo under phy-
siological vitamin-A replete conditions. For example,
RARa1 appears to control the normal neonatal and pub-
ertal morphogenesis of the mammary gland, most likely
by controlling the size of the mammary stem cells
(MaSCs) and progenitor compartments. Importantly,
efficient wnt1-induced oncogenesis appears to be depen-
dent on properly maintained MaCS/progenitor hierarchy.
The RARg isotype most likely has an opposing function.
These unexpected results, together with recent publica-
tions by us and others, reveal the complexities of the
RAR-signaling networks and suggest that to be success-
ful, anti-breast cancer therapy will have to consider these
newly identified intricacies.
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